Trial Profile
Viral kinetic study of VX 135 monotherapy in patients with genotype 1 hepatitis C and cirrhosis, and in patients with genotypes 2, 3 or 4 HCV infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 May 2013
Price :
$35
*
At a glance
- Drugs VX 135 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 May 2013 New trial record
- 30 Apr 2013 Results were presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a Vertex Pharmaceuticals media release.
- 23 Apr 2013 Results from this trial will be presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a Vertex Pharmaceuticals media release.